A sustained response was observed in pediatric patients with juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis or extended oligoarthritis treated with etanercept over 96 weeks with no serious adverse events, according to recently published research.
Researchers analyzed data from the CLIPPER phase 3 trial of pediatric patients with different forms of arthritis with at least two affected joints. Most patients had inadequate responses to traditional disease-modifying antirheumatic drugs (DMARDs), including methotrexate, hydroxychloroquine, cholorquine or sulfasalazine, or NSAIDs. Patients were excluded in the presence of prior experience with biologic agents.
Of 127 patients, including 60 with extended oligoarthritis, 38 with enthesitis-related arthritis and 29 with psoriatic arthritis, 109 entered part two of the study and received treatment for 96 weeks. Concomitant DMARDs were received by 82.8% to 91.7% of patients with different rheumatic diseases.
At week 12 of treatment with etanercept (Enbrel, Amgen), an ACR30 response was achieved in 85.8% of patients, an ACR50 response was observed in 78% of patients, an ACR70 was observed in 59.1% of patients and 28.3% of patients met an ACR90 response, while an ACR100 response was met by 22% of patients.
At week 96, the responses increased to 84.3% of patients at an ACR30 response, 83.5% at ACR50, 78.7% at ACR70, 55.1% at ACR90 and 45.7% at ACR100. Response rates were consistent among all ages. Inactive disease criteria was met by 14.2% of the overall study group at week 12, and by 33.9% at week 96. – by Shirley Pulawski
Disclosure: The researchers report the research was sponsored by Wyeth, which was acquired by Pfizer in 2009. Please see the full study for a list of all other authors’ relevant financial disclosures.